Moderna is coming after your TLR5 with Flagellin
Moderna is coming after your TLR5 with Flagellin
Deliberate attack on your immune system with fragments of Bacteria is written into Pfizer and Moderna Coronavirus jab patents. Moderna loves Flagellin best.
In previous articles, I showed that Pfizer likes to have Escherichia coli cell wall Endotoxin residues in their jabs1, especially Lipid A2 as a cost-free, built-in “Adjuvant” targeting your Lymphatic system3 via the TLR4 pathway to create Cytokine Storm.4
Details of Moderna Covid19 jabs production are less well known, but we can learn from their patents5 which tell us they like to target TLR5 with another bacterial fragment called Flagellin, a polymer found in the “tails” that help the bacteria swim and gather together. They seem to like Salmonella among the many flagellated bacteria options.
“In some embodiments, the RNA ( e.g., mRNA ) vaccine includes an mRNA that encodes a fusion protein of Flagellin and one or more antigenic polypeptides.”
Let’s look first at the pathways of Flagellin harm outlined in an excellent review.6
Figure 1 from the paper by Hajam and coworkers simplifies Flagellin attack on cells and the response.
Signal transduction by flagellin in mammalian cells. Immune cells respond to extracellular monomeric flagellin through either TLR5 homodimer or heterodimer complexes, resulting in the transcription of a variety of genes that are important for the proper stimulation of immune cells. Signaling through TLR5 occurs through a MyD88-dependent adapter molecule that passes the signal to the MAPK and IkB cascades via IRAK, TRAF6 and TAK1. The MAPK and IkB cascades result in the induction of transcription factors AP-1 and NF-kB, respectively. These two transcription factors induce a variety of genes involved in innate and adaptive immunity. Signaling through TLR5/ TLR4 is MyD88-independent and occurs via the IRF3 pathway, which results in the production of IFN-β. Subsequently, IFN-β induces iNOS gene transcription through the activation of STAT1, which culminates in the production of NO. However, when intracellular flagellin is introduced into the host cell cytoplasm via the type III secretory system by some bacteria, it is detected by NLRC4, which culminates in the secretion of IL-1 β via active caspase-1. AP-1, Activator protein-1; GRO, growth-related oncogene; hBD, human beta defensins; IRF3, interferon response factor 3; IRAK, IL-1 receptor associated kinase; LRR, leucine-rich repeats; MAPK, mitogen-activated protein kinase; MCP, monocyte chemoattractant protein; MIP, macrophage inflammatory protein; MyD88, myeloid differentiation factor 88; NBD, nucleotide-binding domain; NF-κB, nuclear factor ‘kappa-light-chain-enhancer’ of activated B cells; PYR, pyrin domain; TAK1, transforming growth factor-beta-activated kinase 1; TBK1. TANK-binding-kinase-1; TLR, Toll-like receptor; TRAF6, TNF receptor associated factor 6; TRIF, TIR domain containing adapter inducing interferon-β; STAT1, signal transducer and activator of transcription 1.
Hajam and coworkers Figure 3 shows Flagellin interactions with different kinds of immune and non-immune cells.
Flagellin directly activates a number of immune and non-immune cells, including T, B, DCs, NK and non-lymphoid cells (macrophages, epithelial, fibroblasts, stromal cells and neutrophils), through TLR5. The cumulative effect of this activation is the augmentation of immune responses through the generation of more potent antibodies and a Th1 response. Moreover, the interaction of flagellin with TLR5 culminates in the production of chemokines from a number of lymphoid and non-lymphoid cells, which results in the generalized recruitment of T and B cells to LNs, which maximizes the chances of an encounter with their cognate antigen and subsequent elicitation of potent immune responses. Instead of TLR5, polymerized flagellin directly stimulates B cells by cross linking BCRs, which might generate antibody responses of the IgM type.
Near the email length limit, so please come back later for more on this Flagellin toxin if interested and share with friends.
Patent ruled Invalid by European Patent Office
According media reports:
BioNTech said on Tuesday (21 November 2023) the European Patent Office has declared as invalid an mRNA patent that has been invoked by Moderna in litigation about alleged an patent violation by BioNTech and its partner Pfizer.
"We understand and welcome the European Patent Office’s decision to revoke Moderna’s European Patent 3 718 565 B1," the German biotech firm said in a statement.
This will throw a major spanner in the mRNA Flagellin attack on Humans planned by Moderna.7
Giuseppe Ciaramella and Sunny Himansu. 2020. BETACORONAVIRUS MRNA VACCINE. United States Patent. 10,702,600 B1. Assigned to Moderna TX, Inc. Continuation of application No. 16 / 368,270 , filed on Mar. 28 , 2019 , which is a continuation of application No. 16 / 040,981 , filed on Jul . 20 , 2018 , now Pat . No. 10,272,150 , which is a continuation of application No. 15 / 674,599 , filed on Aug. 11 , 2017 , now Pat . No. 10,064,934 , which is a continuation of application No. PCT / US2016 / 058327 , filed on Oct. 21 , 2016.
Hajam IA, Dar PA, Shahnawaz I, Jaume JC and Lee JH. Bacterial flagellin - a potent immunomodulatory agent. https://www.nature.com/articles/emm2017172
Giuseppe CIARAMELLA and Sunny HIMANSU. Assigned to ModernaTX, Inc. Cambridge, MA 02139 (US). RESPIRATORY VIRUS VACCINES IMPFSTOFFE GEGEN ATEMWEGSVIRUS VACCINS CONTRE LE VIRUS RESPIRATOIRE. EUROPEAN PATENT SPECIFICATION. EP 3 718 565 B1.